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Objective: Growth hormone (GH) is known to be required for physical well-being.  
Whilst it is also widely believed to be important for quality of life (QoL) and 
psychological health, there is less supportive evidence. The objective of this study 
was to investigate the psychological effects of discontinuation of GH replacement 
from adults with severe GH deficiency (GHD). 
 
Design: A double-blind, placebo-controlled trial in which GH replacement therapy 
was discontinued for 3 months from 12 of 21 GH-deficient adults, where 9 continued 
with GH replacement. 
 
Patients: GH-treated adults (10 men, 11 women), all with severe GHD (peak GH < 
7.7 mU/L on provocative testing), mean age 44.9 years (range 25–68 years). 
 
Measurements: Semi-structured interviews were given at baseline and end-point 
plus questionnaires that included a new hormone-deficiency specific, individualised, 
QoL questionnaire (HDQoL), the General Well-being Index (GWBI), the Well-being 
Questionnaire (W-BQ12), Short-Form 36 health status questionnaire (SF-36), the 
Nottingham Health Profile (NHP) and the General Health Questionnaire (GHQ). 
 
Results: Three months after baseline the serum total IGF-I of placebo-treated 
patients fell from normal, age-related levels (mean 26.6 ± 13.2 nmol/ L) to levels 
indicative of severe GHD (11.6  ± 6.6 nmol/ L) (P <0.001). Psychological symptoms 
of GH withdrawal, reported in interviews at end-point by placebo-treated patients, 
included decreased energy, and increased tiredness, pain, irritability and depression. 
Patients who believed they knew which treatment they had received, correctly 
identified the treatment (GH or placebo) at end-point  (χ2  = 11.25, P <0.01). 
Significant between-treatment-group differences in change scores were found for 
SF-36 General Health (P <0.05), W-BQ12 Energy (P <0.01) and HDQoL do 
physically (P <0.05), indicating reduced general health, reduced energy and greater 
perceived impact of hormone deficiency on physical capabilities in the placebo-
treated group at end-point relative to GH-treated patients.  
 
Conclusion: Withdrawal of GH-treatment from adults with severe GHD has 





The physiological effects of GHD in adults and the beneficial effects of GH 
replacement are well documented (Carroll et al., 1998). Psychological aspects of 
adult GHD are also important (Powrie et al., 1995; Bengtsson et al., 2000), but 
consistently demonstrating psychological benefits of GH treatment in placebo-
controlled studies has proved elusive, perhaps because the measures have been 
insufficiently sensitive. Psychological effects (as measured by the frequently-used 
Nottingham Health Profile (NHP) (Hunt & McKenna, 1989) and/or the Psychological 
General Well-being Index (PGWB) (Dupuy, 1984), in placebo-controlled trials of 6 
months’ GH treatment include increased energy (McGauley et al., 1990; Mardh et al., 
1994; Carroll et al., 1997; Wallymahmed et al., 1997); better emotional functioning 
(Carroll et al., 1997); increased physical mobility and social functioning (Attanasio et 
al., 1997; Carroll et al., 1997); reduced depression (McGauley et al., 1990); 
increased general health, positive well-being and vitality (Carroll et al., 1997). Other 
studies have not found significant effects using the NHP (Whitehead et al., 1992) or 
PGWB (Whitehead et al., 1992; Burman et al., 1995; Baum et al., 1998). Spouses or 
partners have noted significant positive changes in patients 21 months after starting 
GH treatment (Burman et al., 1995). 
 
Many adults have been receiving GH for many years (Gibney et al., 1999). Long-term 
treatment is expensive and the treatment regimen of daily injections inconvenient for 
patients. It is important to determine whether discontinuation of long-term treatment 
has deleterious effects. The few studies investigating the effects of discontinuation of 
GH replacement have shown that GH withdrawal has detrimental effects on some 
physiological variables. Body fat increases and lean mass decreases (Sönksen et al., 
1991; Biller et al., 2000), abdominal obesity and other cardiovascular risk factors 
increase in young people (aged 16 to 21 years) (Johannsson et al., 1999), although 
bone mineral density does not, however, return to pre-GH-treatment levels (Biller et 
al., 2000). Deterioration in psychological well-being was noted in some small studies 
of discontinuation, but was either not significant or reports were anecdotal.  In one 
study, one of the 13 patients, whose GH therapy was discontinued, withdrew 
prematurely from the study owing to increased depression (Biller et al., 2000). All 4 
patients in another study (Bengtsson et al., 1993) tended to have worse scores on 
the Comprehensive Psychopathological Rating Scale (Asberg et al., 1978) 26 weeks 
after GH-withdrawal, 2 patients had worse scores on the Symptom Check-List-90 
(Derogatis et al., 1983), with one patient evaluated for mild depression. In another 
study, 3/10 patients ‘felt totally unable to continue’ with GH withdrawal after 3 months 
and were restarted on GH treatment, and after 6 months, 6 of the remaining 7 
patients asked to restart treatment (Sönksen et al., 1991). A prospective investigation 
of the effects of discontinuation in a sample of 16 to 21 year olds with childhood 
onset of GHD (Wiren et al., 2001), noted increased anxiety in those patients later 
determined to be GH-deficient in adulthood (N = 21) compared to those who were 
GH-sufficient as adults (N = 19), decreased sociability and changes in 
responsiveness and memory. Furthermore 3 patients in the GH-deficient group 
withdrew from the study owing to severe psychological symptoms and were restarted 
on GH therapy. 
 
The psychological objectives of the present randomised, placebo-controlled study 
were to investigate the effect of 3 months’ GH withdrawal on quality of life (QoL), and 
related patient reported outcomes of perceived health and psychological well-being in 
adults with GHD. It was hypothesised that after 3 months’ GH withdrawal placebo-
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treated patients would exhibit, relative to baseline, increased negative well-being 
(depression and anxiety); but decreased energy/ vitality, perceived health, physical 
mobility/ functioning, social functioning, and positive well-being; and that patients’ 
present QoL would deteriorate; but that the GH-treated group would show little 
change.  
 
Patients and Methods 
Design 
Patients were allocated to placebo or continued treatment with GH in a randomised, 
double-blind, placebo-controlled, parallel-groups study, in which patients self-
administered either GH (0.125 to 0.25 IU/ kg body weight/ week) or placebo for a 
period of 3 months. Lilly Industries Ltd supplied the vials of GH (Humatrope) which 
were indistinguishable from placebo. IGF-I was measured at baseline, 1 month later 
and at end-point, by double-antibody radioimmunoassay after acid/ ethanol 
extraction, using a commercially available reagent pack (Amersham, Arlington Hts., 
Ill., within-assay coefficient of variation < 5%). 
 
Patients 
Inclusion criteria: All participating patients had received GH-replacement therapy for 
at least six months immediately prior to the study; were aged between 22 to 70 
years; were severely GH deficient as determined by an Insulin Tolerance or Pituitary 
Function Test in which a dose of insulin reduced the blood glucose to ≤2.0 mmol/ L 
with peak GH concentration of 7.7 mU/L; had received appropriate adrenal, thyroid 
and gonadal hormone replacement therapy, as required by their hormonal condition, 
for at least 12 months prior to the study; were taking adequate contraception (women 
of childbearing age and potential). Exclusion criteria: these included diabetes mellitus 
and active malignancy and are fully described in McMillan et al., 2003.  
 
Of the 144 GH-treated adults with GHD at the study centre only 66 fulfilled the 
stringent inclusion criteria and were approached.  However, 62% declined to 
participate, the majority because they were satisfied with their current treatment – not 
wishing to risk the 50:50 chance of withdrawal. Twenty-two patients were finally 
recruited, but one patient withdrew from psychological aspects of the study just prior 
to baseline.  Another patient, (Placebo group), withdrew suddenly and prematurely, 2 
weeks before end-point, owing to adverse symptoms, but she was interviewed and 
completed some questionnaires. The study sample was representative of the patient 
pool in terms of age and sex. 
 
Sex ratio, age, and duration of previous GH treatment were very similar in the two 
treatment groups, (Table 1), and the proportion of childhood onset (COGHD) and 
adult onset (AOGHD) patients was not significantly different. At baseline, the Placebo 
group had significantly higher Body Mass Index (BMI) (31.3 kg/ m2) compared with 
the GH-treatment group (24.7) [t(14.35) = 2.57, P < 0.05].  
 
All patients were attending the Endocrine Clinic of St Thomas’ Hospital, London and 
gave informed consent to their participation. The Guy’s and St Thomas’ Hospital 
Trust Ethics Committee approved the study. 
 




Questionnaires, semi-structured interviews were given at baseline and end-point, 3 
months later.  
(1) The questionnaires 
A battery of several questionnaires measuring QoL and aspects of health status and 
psychological well-being were administered. Two measures of health status: the NHP 
and Short-form 36 (SF-36) (Ware & Sherbourne, 1992); 2 measures of psychological 
well-being: the General Well-being Index, (GWBI) (Hunt & McKenna, 1992) – British 
version of the PGWB, and the 12-item Well-being Questionnaire (W-BQ12) (Bradley, 
1994; Bradley, 2000); a measure of condition-specific QoL: the Hormone 
Deficiency-Dependent Quality of Life questionnaire (HDQoL) (Bradley, 1999; 
McMillan & Bradley, 2000; McMillan, 2001). The reliability and validity in adult GHD 
of these measures have been reported previously, (McMillan & Bradley, 2000) and 
(McMillan, 2001) (PhD thesis). Two other measures were used: the General Health 
Questionnaire (GHQ-30) (Goldberg & Williams, 1988) and an English version of a 
Swedish questionnaire (Burman et al., 1995) for completion by spouses or partners, 
to measure their view of changes in patients during the study. 
 
Description and scoring of measures 
SF-36: Eight subscales to measure Bodily Pain, General Health, Mental Health, 
Physical Functioning, Role-Emotional, Role-Physical, Social Functioning and Vitality. 
Score range 0 to 100 (poor to good health status). 
NHP: Six subscales to measure Emotional Reactions, Energy, Pain, Physical 
Mobility, Sleep and Social Isolation. Score range 0 to 100 (good to poor health 
status).  
W-BQ12: Three subscales to measure Negative Well-being, Positive Well-being and 
Energy. Score range 0 to 12 (higher scores indicating increased mood of the 
subscale label) and a General Well-being total (range 0 to 36 with higher score 
indicating better well-being). 
GWBI: A Total score, range 0 to 100, (higher score indicating reduced well-being). 
HDQoL: A recently developed individualised questionnaire to measure individuals’ 
perceptions of the impact of their hormonal condition and its treatment on their QoL 
in 13 domains of life. The domains include family life, sex life, physical appearance, 
physical capabilities (do physically), motivation and confidence. For example, in the 
domain do physically, patients are asked about the impact of hormone deficiency on 
the things they can physically do.  A “not applicable” option is provided for domains 
that may not be applicable to any individual. Otherwise, respondents rate the impact 
of the hormonal condition on each domain and the importance of that domain. These 
two scores are multiplied to provide a weighted impact score ranging from -9 to +9 
(maximum negative to maximum positive impact of hormone deficiency on that 
domain). Weighted domain scores are summed and divided by the number of 
applicable domains to give the HDQoL Average Weighted Impact score (HDQoL 
AWI), (range from -9 to +9), the maximum negative to maximum positive weighted 
impact of hormone deficiency on overall QoL. Domains can be analysed separately. 
Spouse/ partner Questionnaire (SPQ): The 12-item questionnaire was designed for 
spouses or partners to assess any changes in mood and behaviour of adults with 
GHD. The original Swedish version was translated into English using a native English 
speaker fluent in Swedish, and this English translation was compared with an English 
version produced by the author (Dr Burman).  A native Swedish expert was also 
consulted, and 4 items (concerning self-confidence, memory, concentration, and 
stress tolerance) were added to the English translation by native English language 
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speakers experienced in questionnaire design. The patient may nominate a spouse, 
partner, relative or friend to complete the questionnaire, and that person chooses 
between a negative change (scoring –1) in the patient over the study period, a 
positive change and no change (both scoring 1). Domains are analysed separately. 
The SPQ was not validated psychometrically before use. 
GHQ-30: The 30-item self-completion measure detects non-psychotic psychiatric 
disturbance and/or affective disorders, with items on depression, anxiety and social 
function. The total score ranges from 0 to 90, (low to high psychological distress).  
 
(2) Interviews 
Semi-structured interviews were held at baseline and end-point. The number of 
serious negative life events and difficulties occurring in the 12 months prior to end-
point was assessed in the end-point interviews, using a short checklist [Life events 
and difficulties screening checklist (unpublished, available from Dr Bernice Andrews, 
at Psychology Department, Royal Holloway, University of London, Egham, Surrey, 
TW20 0EX)] modified from a screening checklist for stressful life events and chronic 
difficulties (Costello & Devins, 1998). Negative life events and difficulties that 
occurred not only during the 3-month study period, but also in the months before the 
study, might precipitate depression during the study. 
 
Statistical analyses 
Between-treatment-group differences in questionnaire change scores over the 
withdrawal period were tested using t-tests or Mann-Whitney tests. Several 
questionnaires have multiple end-points (e.g. the SF-36, with 8 subscales). In order 
to minimise the number of false positive conclusions that may be derived from the 
many tests to be carried out within such questionnaires but, at the same time, 
minimising what might be considered overly severe adjustments for multiplicity of 
end-points entailed by the Bonferroni correction for familywise error, adjustments 
were carried out in the following way. Previous clinical experience strongly suggested 
that certain variables were most likely to be affected by GH withdrawal, but for other 
variables previous experience did not allow specific directional hypotheses to be 
formulated. The variables within any questionnaire that had subscales or multiple 
end-points were therefore divided into 2 ‘families’: a confirmatory family (of variables 
within the questionnaire for which predictions were made), and an exploratory family 
(of questionnaire variables for which no predictions were made). The Bonferroni 
correction for familywise error was then based on the number of variables in the 
family to which that variable belonged. That is, alpha was set initially to 0.05/n where 
n was the number of variables within the family.  Thus, in questionnaires where there 
were several variables, the numbers of exploratory variables did not prevent the 
confirmatory variables from reaching significance and vice-versa.  In addition to these 
procedures, the Holm’s sequential Bonferroni procedure (Holm, 1979) was employed 
within each family, whereby the family size reduces with each significant result. One-
sided tests were performed in the confirmatory family and two-sided tests in the 
exploratory family. (See Table 2).  Frequencies of positive and negative change in 
the treatment groups found by spouse/ partners (SPQ) were compared using 
Chi-Square tests.  
 
(Table 2 here) 
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Results 
Biochemical changes  
Three months after baseline the serum total IGF-I of placebo-treated patients fell 
from normal, age-related levels (mean 26.62 ± 13.24 nmol/ L) to levels indicative of 
severe GHD (11.6  ± 6.65 nmol/ L) (P <0.001). Only a small, non-significant decrease 
was noted in GH-treated patients. One patient in the GH-treatment group reported 
several adverse symptoms. A large drop (-20.2 nmol/L or 39.3%) in his IGF-I levels 
were noted over the study, well outside the mean change of -1.74 ± 10.68 for the 
GH-treatment group and more than the mean change of -15.02 ± 12.38 in IGF-I 
levels for the Placebo group. However, his IGF-I level at end-point (31.2) was in the 
normal range. After study codes had eventually been broken, the patient was asked if 
there were any reasons for this result. He suggested that the injection pen may have 
malfunctioned. It was also possible that he did not fully adhere to the injection 
regimen as he had a history of non-adherence. Analyses were therefore undertaken 
excluding this anomalous patient’s data. The mean drop in IGF-I levels within the 
Placebo group for men (20.4 ± 13.8) was over twice that of women (9.63 ± 8.81) but 
not significantly greater on a t-test (P = 0.138). 
 
Interviews 
There were interesting sex differences in reporting of symptoms of GH-withdrawal at 
end-point with placebo-treated women tending to describe more symptoms of 
withdrawal and greater severity of symptoms than men (Table 3). Placebo-treated 
women: all reported loss of energy/ stamina as being the prime symptom during the 
withdrawal; some showed changes in sleep patterns with overwhelming feelings of 
daytime drowsiness. Five reported unprovoked crying episodes and 3 reported 
depressed mood. There was increased irritability and intolerance of others. Physical 
symptoms noticed were: changes in hair condition, and in growth of hair and nails, 
increased skin dryness, increased bruising, increased joint pain and muscle aches 
particularly associated with exercise. Placebo-treated men: The 3 youngest men 
noticed reduced energy levels after GH withdrawal. There were reports of weight 
gain, muscle aches and joint pain. The three oldest men (aged 53 to 66 years) 
reported very few effects of withdrawal: two reported increased weight, and one no 
symptoms at all. Three placebo-treated patients reported negative life events/ 
difficulties.   GH-treated patients: Five patients reported no changes in QoL, health or 
well-being over the study, but two women reported some changes in such areas as 
depression and tiredness owing to family problems and another woman had noticed 
some minor symptoms for which she had no explanation. The GH-treated male 
whose IGF-I levels fell by 39% over the study, and who may not have fully adhered to 
the injection regimen, experienced some typical symptoms of GHD.  He reported 
depression; reduced energy, fitness and immune function; increased drowsiness, 
irritability and abdominal adiposity; changes in sleep pattern and skin.  
 
Patients were asked at end-point whether they thought they had been receiving GH 
or placebo over the withdrawal period. Whilst all 6 placebo-treated women suspected 
that they had been receiving placebo, only 3 of the 6 men suspected, the others were 
not sure. Five of 9 GH-treated patients believed they had received their usual GH 
during the study, 1 believed the injections were placebo, and 3 were not sure.  A 
Fisher’s exact test, performed on those volunteering an opinion on their treatment-
group allocation, found a significant difference between expected and actual 
frequencies in cells (χ2 = 11.25, P <0.01).  Thus, when patients believed they knew 
which treatment they had been receiving, they correctly identified the treatment group 
 8
to which they had been assigned. Whilst the drop in IGF-I values for placebo-treated 
men was over twice that for women, women reported more symptoms than men and 
these symptoms tended to be more extreme.  All 6 women had strong suspicions that 
they had received placebo, compared to only half the men.  This poses the question 
whether women might be more sensitive psychologically than men to smaller 
changes in IGF-I levels resulting from GH withdrawal. 
 
(Table 3 here) 
 
Questionnaire data 
Analyses were conducted excluding the above-mentioned anomalous case, the male 
patient in the GH-treatment group whose drop in IGF-I levels was so extreme and 
who may not have fully adhered to the injection regimen. The placebo-treated female 
patient who withdrew from the study 2 weeks before end-point, owing to adverse 
symptoms, only completed the W-BQ12 and GHQ questionnaires at this stage, and 
these data were included in the questionnaire analysis.  The only significant 
between-treatment-group difference in baseline scores, once Bonferroni corrections 
had been applied, was for the HDQoL domain holiday (P = 0.001). Significant 1-tailed 
between-group differences in change scores were found for SF-36 General Health 
[t(17) = 2.76, P = 0.007 (required P after Bonferroni correction: 0.01)], W-BQ12 
Energy [t(18) = 3.25, P = 0.002 (required P: 0.017)], and HDQoL domain do 
physically [t(16) = 2.47, P = 0.013 (required P: 0.017)] where patients are asked 
about the impact of hormone deficiency on the things they can do physically. SF-36 
Mental Health was close to required 1-tailed significance of 0.013 [t(17) = 2.41, P = 
0.014]. (See Table 4). Thus, on GH discontinuation Placebo-group patients showed 
significantly greater change and in the direction of decreased general health (SF-36), 
decreased energy (W-BQ12) and greater perceived impact of hormone deficiency on 
physical capabilities (HDQoL) than GH-treated patients (whose scores tended to 
improve over the study). Analysis of the single SF-36 health transition item showed 
that, by end-point, 4 Placebo-treated patients considered their health worse than one 
year before, but no GH-treated patients, (not significant on a Chi-Square test, P = 
0.103). There were no significant findings for the NHP and GWBI questionnaires. 
 
There were no significant differences between the treatment groups in change in 
GHQ-30 Total (Table 4). The GHQ-30 score of the placebo-treated female who 
withdrew from the study prematurely, increased from 28.0 at baseline to 69.6 two 
weeks before end-point, indicative of significant psychological distress. Two patients 
preferred not to nominate anyone to complete the Spouse/ partner Questionnaire. 
Excluding the data of the anomalous case in the GH-treatment group, negative 
change was reported by spouse/ partners of patients in both treatment groups and 
there were no significant differences in reports of negative change.  
 
Although interviews showed sex differences in reporting of symptoms at end-point, 
this was not reflected in significant sex differences in change in questionnaire scores. 
There were no significant between-group differences in numbers of life events and 
difficulties on a Mann-Whitney test (P = 0.62) that might account for between-group 
differences in psychological variables.  
 
(Table 4 here) 
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Discussion 
This randomised double-blind, placebo-controlled study has demonstrated for the 
first time that when GH replacement is discontinued for 3 months from adults with 
severe GHD there are detrimental psychological effects.  In particular these patients 
experienced significantly decreased general health (SF-36), significantly decreased 
energy (W-BQ12) and significantly greater perceived impact of hormone deficiency 
on physical capabilities (HDQoL) in comparison with patients whose GH therapy 
continued throughout the study.  Trends (albeit non-significant) were in the expected 
direction of worsening QoL, well-being, and health status for the great majority of 
variables in patients whose GH was discontinued. Women tended to report more 
symptoms of withdrawal and greater severity of symptoms than men in interviews, 
though there were only non-significant trends in this direction in questionnaire data. 
In general the findings support those of other studies that reported increased 
depression following GH discontinuation (Bengtsson et al., 1993; Biller et al., 2000). 
The scores of GH-treated patients tended to improve over the study, but not 
significantly so. All questionnaires except the GHQ-30 and SPQ had the advantage 
of having been previously validated psychometrically for use with adults with GHD 
(McMillan & Bradley, 2000). This study confirmed the sensitivity to change of the SF-
36 in adult GHD found in a recent study (Bernabeu et al., 2002). Although the 
HDQoL, and W-BQ12 had not previously been used in trials of GH replacement, this 
study showed them to be sensitive to change, but the frequently used NHP and the 
British version of the PGWB (the GWBI) were not sufficiently sensitive.  
 
Interesting and rich qualitative data emerged from the interviews. The key 
psychological symptoms of GH discontinuation reported by placebo-treated patients 
were reduced energy, increased daytime drowsiness, crying episodes, depression 
and irritability.  Reported physical symptoms included increased pain in joints and 
muscle aches, weight gain and changes to skin, hair and nails. The interview data 
were highly compatible with results obtained from questionnaire analysis, both 
significant and trends, and particularly with respect to energy where 9/12 patients 
reported reduced energy by end-point, giving rise to a significant result for W-BQ12 
Energy.  Reduced energy and reported physical symptoms are likely to explain the 
significant effects of GH discontinuation on perceived general health (SF-36) and 
physical capabilities (HDQoL).  Interview reports of increased depression, crying 
episodes and increased irritability support the trend towards reduced mental health 
(SF-36) that approached significance. 
 
It is interesting that 75% of Placebo-group patients (and all the women in that group) 
strongly and correctly suspected that they were in the Placebo group.  This was 
prompted by the return of symptoms they had experienced before receiving GH 
treatment in the first place, and in some cases more extreme or new symptoms. 
Others have noted, in double-blind, placebo-controlled studies of GH treatment 
provision to adults with GHD, that suspicions of patients as to treatment group were 
correct (Degerblad et al., 1990), or that clinicians’ suspicions proved correct when a 
study’s randomisation codes were broken (Sönksen et al., 1991).  Clinicians may see 
large changes in IGF-I levels, body composition or metabolic factors over the course 
of a study - changes that can only be explained by the effects of GH treatment or its 
withdrawal. Neither patients nor clinicians are likely to be all truly ‘blind’ in these 
studies of GH treatment.  
 
The SPQ yielded no significant differences in reports of negative change over the 
withdrawal period by spouse/ partners. It is possible that the 3-month period was too 
short for changes to become very noticeable to spouse/ partners, even if the patients 
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themselves had noted changes.  In a previous study (Burman et al., 1995) significant 
positive change was reported by spouse/ partners 21 months after introduction of GH 
treatment, and with a larger sample than the present study. The SPQ (now adapted 
for use in the UK) could be useful in larger studies (but will require psychometric 
validation), and it may be more sensitive to change when patients are first given GH 
therapy, when predominantly positive changes might be expected. One general 
problem with such a questionnaire is that many patients have neither spouse nor 
partner, particularly if they have COGHD (Rikken et al., 1995).   Friends, though 
willing to complete the questionnaire, may not be in a good position to notice subtle 
changes in a patient’s mood or various aspects of life.  
 
There were recruitment difficulties for this study, as the majority of patients declined 
to participate because they did not want to risk withdrawal from GH-treatment. This 
study has shown that they were right in anticipating detrimental effects of 
discontinuation, even for a short period of 3 months.  However, it should be noted 
that some patients (the older men) tolerated withdrawal from GH well, with no 
perceived symptoms other than weight gain (for 2 men) over the 3-month period.  
Unfortunately the small pool of patients willing and suitable for inclusion resulted in a 
small sample of 21 patients, albeit representative of a much larger pool of patients at 
this single centre. The possible non-adherence to the study protocol of one patient in 
the GH-treatment group also reduced the data available for analysis. Furthermore, 
one patient in the placebo group withdrew from the study just prior to end-point owing 
to adverse symptoms, but the interview conducted at this point showed her to be 
experiencing considerable psychological distress, confirmed by a high GHQ-30 
score.  
 
Note that the method of analysis reported here and the results for the SF-36 differ 
slightly from those already published in this journal (McMillan et al., 2003) owing to 
the need to accommodate the opinions of different reviewers on the controversial 
issue of the best method of correcting for multiplicity of end-points, without applying 
too severe criteria which could result in Type II errors.    
Conclusion 
Three months’ withdrawal of GH treatment from GH-treated adults with severe GHD 
had detrimental psychological effects, particularly in terms of energy, general health 
and physical capabilities. 
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Table 1: Characteristics of study participants  
 Placebo-treated  
(N = 12) 
GH-treated 
(N = 9) 
P 
Men  6  4  
Women  6  5  
Mean age at baseline (years) [range] 45.8 [25 – 68] 43.8 [25 - 66]  
Mean duration of GH treatment (months) [range] 61 [12 - 132] 60 [18 - 132]   
COGHD : AOGHD ratio  2 : 10  4 :  5  
BMI at baseline (kg/ m2) 31.3 ± 8.3 24.7 ± 2.9 < 0.05 
Isolated GHD  0  2  
Gonadal hormone deficiency   8  6  
Thyroid hormone deficiency  9  5  
Corticosteroid deficiency 10  5  
Antidiuretic hormone deficiency  1  1  
Acromegaly  0  1  
Cushing’s disease  4  1  
Craniopharyngioma  1  1  
Chromophobe adenoma  4  1  
Macroprolactinoma  1  1  
Prolactinoma  1  1  




Table 2: The Holm’s sequential Bonferroni corrections employed in 
questionnaires with multiple end-points. 
Questionnaire n {Variables for which 
predictions were made} 
[Confirmatory alpha levels*]  
n {Variables for which no 
predictions were made} 
[Exploratory alpha levels*] 
HDQoL 3 {QA: present QoL. Domains: Do 
physically, Social life} 
[0.017, 0.025. 0.05] 
12 {QB: impact on QoL. All 11 
remaining HDQoL domains}  
[0.004, 0.0045, 0.005 etc.] 
NHP 4 {Emotional Reactions, Energy, 
Physical Mobility, Social Isolation} 
[0.013, 0.017, 0.025 etc.] 
2 {Pain, Sleep}  
[0.025, 0.05] 
 
SF-36 5 {General Health, Mental Health, 
Physical Functioning, Social 
Functioning, Vitality}  
[0.01, 0.013, 0.017 etc.] 
3 {Bodily Pain, Role-Emotional, 
Role-Physical} 
[0.017, 0.025, 0.05] 
 
W-BQ12 3 {Negative Well-being, Energy, 
Positive Well-being}  
[0.017, 0.025, 0.05] 
- 
n: the number of variables within each family (of either exploratory or confirmatory variables). 
*Required alpha levels increasing for each significant result using Holm’s sequential 
Bonferroni procedure. 
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Table 3: Key symptoms reported by Placebo-treated patients at end-point 




Loss of energy 6 3
Increased drowsiness 4 1
Change in sleep pattern 4 1
Depression 3 1
Crying episodes 5 -
Increased irritability/ intolerance 3 1
Change in memory and concentration 3 -
Decreased sociability 2 1
Increased aches and pains 3 1
Changes in hair/ skin/ nails 3 1
Weight gain 1 3
 
Believed randomised to Placebo group 6 3
Women: N = 6, mean age 45.5 years 
Men: N = 6, mean age 46 years 
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Table 4: Treatment-group means for questionnaires  
Placebo-treated (mean ± SD) GH-treated (mean ± SD)  
Baseline End-point   Baseline End-point  
P 
 
GHQ-30 Total 23.42 ± 9.06 32.79 ± 17.54 18.40 ± 4.58 20.00 ± 4.04  
GWBI Total 47.58 ± 16.40 51.27 ± 19.34 43.25 ± 12.61 41.25 ± 6.32  
HDQoL AWI  0.18 ± 2.29 -1.36 ± 1.14 -2.12 ± 1.20 -1.92 ± 1.44  
**HDQoL do physically -0.25 ± 3.02 -1.80 ± 1.81 -3.50 ± 2.51 -2.38 ± 1.19 0.013* 
NHP Emotional Reactions 13.86 ± 24.46  14.42 ± 24.91  3.78 ± 7.43    0.0 ± 0.0   
NHP Energy 24.95 ± 35.06  26.33 ± 37.89  7.90 ± 15.18   7.90 ± 15.18  
NHP Pain  4.12 ± 10.85   5.17 ± 17.14   4.77 ± 9.44   5.29 ± 12.77   
NHP Physical Mobility  5.42 ± 15.74   7.15 ± 23.73  2.75 ± 7.77  5.42 ± 11.60   
NHP Sleep 17.43 ± 25.98  21.67 ± 29.84   5.16 ± 7.20     0.0 ± 0.0  
NHP Social Isolation 13.13 ± 24.11  13.09 ± 26.10  9.68 ± 14.08    0.0 ± 0.0  
SF-36 Bodily Pain 72.08 ± 20.57 71.55 ± 28.00 70.0 ± 14.05 81.50 ± 27.52  
SF-36 General Health 63.50 ± 19.58 57.00 ± 23.19 62.75 ± 23.89 66.12 ± 25.16  0.007* 
SF-36 Mental Health 75.00 ± 15.92 69.45 ± 21.04 77.5 ± 20.05 84.50 ± 7.23  
SF-36 Physical Functioning 78.52 ± 26.43 72.27 ± 30.20 83.13 ± 14.13 85.63 ± 15.45  
SF-36 Role-Emotional 77.78 ± 35.77 63.33 ± 48.30 87.50 ± 35.36 91.67 ± 23.57  
SF-36 Role-Physical 70.83 ± 39.65 72.73 ± 41.01 84.38 ± 18.60 90.63 ± 12.94  
SF-36 Social Functioning 82.95 ± 25.78 77.27 ± 28.95 93.75 ± 9.45 90.63 ± 12.94  
SF-36 Vitality 60.00 ± 22.76 51.82 ± 28.40 59.38 ± 15.22 60.00 ± 13.63  
W-BQ12 General Well-being 
total 
23.83 ± 9.08 21.83 ± 9.87 25.56 ± 6.21 27.31 ± 3.06  
W-BQ12 Negative Well-being  2.42 ± 2.57  3.00 ± 3.52  1.88 ± 2.8   1.50 ± 1.41   
W-BQ12 Energy  6.83 ± 3.64  5.90 ± 4.12  7.06 ± 2.08  8.13 ± 1.25 0.002* 
W-BQ12 Positive Well-being  7.42 ± 3.32  6.92 ± 2.94  8.38 ± 2.13   8.69 ± 1.75   
 
Minimum N 
12 (W-BQ12, GWBI) 
11 (GHQ, NHP) 
10 (SF-36, HDQoL) 
8 (SF-36, W-BQ12, GWBI) 
6 (HDQoL, GHQ, NHP) 
 
*Significance of between group differences in change scores (1-tailed). 
** Results of significant HDQoL domains only. A more negative score indicates greater negative impact of hormone deficiency 
on the domain. 
Score ranges: GHQ-30: 0 - 90 (from low to high psychological distress).  HDQoL: -9 to +9 (maximum negative to maximum 
positive impact of hormone deficiency.  GWBI and NHP: 0 – 100 (good to poor well-being/ health status).  SF-36: 0 to 100 (poor 
to good health status).  W-BQ12: subscale range 0 – 12 (higher scores indicating increased mood of the subscale label); 
General Well-being total range 0 – 36 (higher score indicating better well-being).  
 15
References 
Asberg, M., Montgomery, S.A., Perris, C.  (1978) Comprehensive Psychopathological 
Rating Scale. Acta Psychiatrica Scandinavica 271, (Suppl.), 5-29. 
Attanasio, A.F., Lamberts, S.W.J., Matranga, A.M.C., Birkett, M.A., Bates, P.C., Valk, 
N.K., Hilsted, J., Bengtsson, B.A. & Strasburger, C.J. (1997) Adult growth 
hormone (GH)-deficient patients demonstrate heterogeneity between 
childhood onset and adult onset before and during human GH treatment. 
Journal of Clinical Endocrinology and Metabolism 82, 82-88. 
Baum, H.B.A., Katznelson, L., Sherman, J.C., Biller, B.M.K., Hayden, D.L., 
Schoenfeld, D.A., Cannistraro, K.E. & Klibanski, A. (1998) Effects of 
physiological growth hormone (GH) therapy on cognition and quality of life in 
patients with adult-onset GH deficiency. Journal of Clinical Endocrinology and 
Metabolism 83, 3184-3189. 
Bengtsson, B.A., Eden, S., Lonn, L., Kvist, H., Stokland, A., Lindstedt, G., Bosaeus, 
I., Tolli, J., Sjostrom, L. & Isaksson, O.G.P. (1993) Treatment of adults with 
growth hormone (GH) deficiency with recombinant human GH. Journal of 
Clinical Endocrinology and Metabolism 76, 309-317. 
Bengtsson, B.A., Johannsson, G., Shalet, S.M., Simpson, H. & Sönksen, P.H. (2000) 
Treatment of growth hormone deficiency in adults. Journal of Clinical 
Endocrinology and Metabolism 85, 933-937. 
Bernabeu, I. J., Gaztambide, S. Menendez, E., Webb, S.M., Garcia-Patterson, A., 
Diaz, M., Ferrer, J., Biarnes, J, Lecube, A., Henrich, G., Herschbach, P., 
Blum, W. & Marin, F. (2002) Characteristics of the Spanish version of the 
quality of life questionnaire (QLSM-H) in adult subjects with growth hormone 
deficiency treated with somatotropin: pilot study. Endocrinologia y Nutricion 
49, 105-112. 
Biller, B.M.K., Sesmilo, G., Baum, H.B.A., Hayden, D., Schoenfeld, D. & Klibanski, A. 
(2000) Withdrawal of long-term physiological growth hormone (GH) 
administration: Differential effects on bone density and body composition in 
men with adult-onset GH deficiency. Journal of Clinical Endocrinology and 
Metabolism 85, 970-976. 
Bradley, C. (1994) The Well-being Questionnaire. In Handbook of Psychology and 
Diabetes: A Guide To Psychological Measurement In Diabetes Research And 
Practice (ed. C. Bradley), pp. 89-109. Harwood Academic Publishers, Chur, 
Switzerland. 
Bradley, C. (1999) Achieving accessibility with quality: questionnaire measurement of 
condition-specific individualised quality of life. Proceedings of the British 
Psychological Society 7, 143. 
Bradley, C. (2000) The12-item Well-being Questionnaire: Origins, current stage of 
development, and availability. Diabetes Care 23, 875. 
Burman, P., Broman, J.E., Hetta, J., Wiklund, I., Erfurth, E.M., Hagg, E. & Karlsson, 
F.A. (1995) Quality-of-Life in adults with Growth-Hormone (GH) Deficiency - 
Response to treatment with recombinant human GH in a placebo-controlled 
21-month trial. Journal of Clinical Endocrinology and Metabolism 80, 3585-
3590. 
Carroll, P.V., Christ, E.R. & Growth Hormone Research Society Scientific Committee 
(1998) Growth hormone deficiency in adulthood and the effects of growth 
hormone replacement: a review. Journal of Clinical Endocrinology and 
Metabolism 83, 382-395. 
Carroll, P.V., Littlewood, R., Weissberger, A.J., Bogalho, P., McGauley, G., Sönksen, 
P.H. & Russell-Jones, D.L. (1997) The effects of two doses of replacement 
growth hormone on the biochemical, body composition and psychological 
 16
profiles of growth hormone-deficient adults. European Journal of 
Endocrinology 137, 146-153. 
Costello, C.G. & Devins, G.M. (1998) Two stage screening for stressful life events 
and chronic difficulties. Canadian Journal of Behavioral Science 20, 85-92. 
Degerblad, M., Almkvist, O., Grunditz, R., Hall, K., Kaijser, L., Knutsson, E., Ringertz, 
H. & Thoren, M. (1990) Physical and psychological capabilities during 
substitution therapy with recombinant growth-hormone in adults with growth-
hormone deficiency. Acta Endocrinologica 123, 185-193. 
Derogatis, L.R., Rickels, K. & Rock, A. (1983) The SCL-90-R.  Administration, 
Scoring and Procedures Manual II. Clinical Psychometric Research, 
Baltimore, MD. 
Dupuy, H.J. (1984) The Psychological General Well-being Index (PGWB). In 
Assessment Of Quality Of Life In Clinical Trials Of Cardiovascular Therapies 
(eds. N. K. Wenger, M. E. Mattson, C. D. Furburg & J. Elinson). Le Jacq 
Publishing Inc, New York. 
Gibney, J., Wallace, J.D., Spinks, T., Schnorr, L., Ranicar, A., Cuneo, R.C., Lockhart, 
S., Burnand, K.G., Salomon, F., Sönksen, P.H. & Russell-Jones, D. (1999) 
The effects of 10 years of recombinant human growth hormone (GH) in adult 
GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 84, 
2596-2602. 
Goldberg, D. & Williams, P. (1988) A User's Guide To The General Health 
Questionnaire. NFER-NELSON, Windsor. 
Henrich, G. & Herschbach, P. (2000) Questions on Life Satisfaction (FLZM) - A short 
questionnaire for assessing subjective quality of life. European Journal of 
Psychological Assessment 16, 150-159. 
Herschbach, P., Henrich, G., Strasburger, C.J., Feldmeier, H., Marin, F., Attanasio, 
A.M. & Blum, W.F. (2001) Development and psychometric properties of a 
disease-specific quality of life questionnaire for adult patients with growth 
hormone deficiency. European Journal of Endocrinology 145, 255-265. 
Holm, S. (1979) A simple sequentially rejective multiple test procedure.  
Scandinavian Journal of Statistics 6, 65-70. 
Holmes, S.J., McKenna, S.P., Doward, L.C., Hunt, S.M. & Shalet, S. (1995) 
Development of a questionnaire to assess the quality of life of adults with 
growth hormone deficiency. Endocrinology and Metabolism 2, 63-69. 
Hunt, S.M. & McKenna, S.P. (1989) The Nottingham Health Profile. In European 
Guide to the Nottingham Health Profile. The European Group for Quality of 
Life and Health Measurement. 
Hunt, S.M. & McKenna, S.P. (1992) A British adaptation of the General Well-being 
Index:  a new tool for clinical research. British Journal of Medical Economics 
2, 49-60. 
Hunt, S.M., McKenna, S.P. & Doward, L.C. (1993) Preliminary report on the 
development of a disease-specific instrument for assessing quality-of-life of 
adults with growth hormone deficiency. Acta Endocrinologica 128, 37-40. 
Johannsson, G., Albertsson-Wikland, K. & Bengtsson, B.A. (1999) Discontinuation of 
growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-
sufficient adolescent patients compared with control subjects. Journal of 
Clinical Endocrinology and Metabolism 84, 4516-4524. 
Mardh, G., Lundin, K., Borg, G., Jonsson, B. & Lindeberg, A. (1994) Growth hormone 
replacement therapy in adult hypopituitary patients with growth hormone 
deficiency: combined data from 12 European placebo-controlled clinical trials. 
Endocrinology and Metabolism 1, (Suppl. A), 43-49. 
McGauley, G., Cuneo, R.C., Salomon, F. & Sönksen, P. (1990) Psychosocial well 
being before and after growth hormone treatment in adults with growth 
hormone deficiency. Hormone Research 33, (Suppl. 4), 52-54. 
 17
McMillan, C. & Bradley, C. (2000) A comparison of the psychometric properties of 
quality of life and related measures (GWBI, W-BQ12, NHP, SF-36 and 
HDQoL) for use in research into adult growth hormone deficiency (GHD). 
Quality of Life Research 9, 1324 (Abstract 1352). 
McMillan, C.V. (2001) A psychometric evaluation of measures of quality of life and 
related health outcomes in adults with growth hormone deficiency. PhD 
Thesis, Royal Holloway, University of London, UK. 
McMillan, C.V., Gibney, J., Russell-Jones, D.L., Sönksen, P.H. & Bradley, C. (2001) 
Psychological effects of withdrawal of growth hormone (GH) therapy from 
GH-deficient adults. Endocrine Abstracts 1, 111. 
McMillan, C.V., Bradley, C., Gibney, J., Russell-Jones, D.L. & Sönksen, P.H. (2003). 
Evaluation of two health status measures in adults with growth hormone 
deficiency. Clinical Endocrinology 58, 436-445.  
Powrie, J., Weissberger, A. & Sönksen, P. (1995) Growth hormone replacement 
therapy for growth hormone-deficient adults. Drugs 49, 656-663. 
Rikken, B., Vanbusschbach, J., Lecessie, S., Manten, W., Spermon, T., Grobbee, R., 
Witt, J.M., Dewaal, H.A.D., Drayer, N.M., Jansen, M., Keizer, S., Oostdijk, W., 
Otten, B.J., Reeser, H.M., Vulsma, T., Waelkens, J.J.J. & Zelissen, P.M.J. 
(1995) Impaired social-status of growth-hormone deficient adults as 
compared to controls with short or normal stature. Clinical Endocrinology 43, 
205-211. 
Sönksen, P., Cuneo, R.C., Salomon, F., McGauley, G., Wiles, C.M., Wilmshurst, P., 
Byrne, C., Hesp, R., Lowy, C. & Weissberger, A. (1991) Growth-Hormone 
therapy in adults with growth-hormone deficiency. Acta Paediatrica 
Scandinavica 379, (Suppl.), 139-146. 
Wallymahmed, M.E., Foy, P., Shaw, D., Hutcheon, R., Edwards, R.H.T. & 
MacFarlane, I.A. (1997) Quality of life, body composition and muscle strength 
in adult growth hormone deficiency: the influence of growth hormone 
replacement therapy for up to 3 years. Clinical Endocrinology 47, 439-446. 
Ware, J.E. & Sherbourne, C.D. (1992) The MOS 36-Item Short-Form Health Survey 
(SF-36). 1. Conceptual-Framework and Item Selection. Medical Care 30, 473-
483. 
Whitehead, H.M., Boreham, C., McIlrath, E.M., Sheridan, B., Kennedy, L., Atkinson, 
A.B. & Hadden, D.R. (1992) Growth-hormone treatment of adults with growth-
hormone deficiency - Results of a 13-month placebo controlled cross-over 
study. Clinical Endocrinology 36, 45-52. 
Wiren, L., Johannsson, G. & Bengtsson, B.A. (2001) A prospective investigation of 
quality of life and psychological well-being after the discontinuation of GH 
treatment in adolescent patients who had GH deficiency during childhood. 
Journal of Clinical Endocrinology and Metabolism 86, 3494-3498. 
 
